Novo Nordisk announces the full launch of Rybelsus (semaglutide tablets), the world's first and currently only oral glucagon like peptide-1 receptor agonist (GLP-1RA), in China. This convenient oral medication helps patients benefit early from GLP-1RA therapies, aiding in blood sugar control and comprehensive metabolic management.

Editor: Gao Han